SESSION TYPE: Sleep III
PRESENTED ON: Wednesday, October 24, 2012 at 02:45 PM - 04:15 PM
PURPOSE: To prove the beneficial advantage of PPI on patients with co-existing OSA and GERD
METHODS: We invited patients with recent OSA by standard Polysomnography (PSG) to participated study. Ambulatory 24-hours pH monitoring was used for abnormal esophageal acid exposure. 26 patients with GERD and OSA were randomized into 2 groups. Rabeprazole (20 mg twice daily) or placebo was used for 6 weeks. Follow up PSG and ambulatory 24-hours pH monitoring was collected.
RESULTS: Overall baseline characteristic and sleep parameters were not statistical significant in 2 groups. In study group, there was statistical significant in reduction of Apnea-Hypopnea Index (AHI), Respiratory-Disturbance Index (RDI), Periodic-Limb Movements (PLM), and improved lowest oxygenation while apnea (SpO2), with all p value <0.05. The Epworth Sleepiness Scale (ESS) and Functional Outcome of Sleep Questionnaire (FOSQ) were not statistically significant.
CONCLUSIONS: PPI can reduced AHI in patients with co-existing GERD and OSA with statistical significant. The ESS and FOSQ were not different between control and placebo groups.
CLINICAL IMPLICATIONS: PPI can reduce AHI in patients with co-existing OSA and GERD. The exact mechanism was not postulated in this study but PPI may reduce upper airway inflammation by inhibition of acid reflux. Further investigations should be focus on the appropriate duration of PPI treatment and follow up sleep parameters.
DISCLOSURE: The following authors have nothing to disclose: Thongchai Leelayuthachai, Nattapong Jaimchariyatam, Sutep Gonlachanwit, Chatchai Kriengkirakul
No Product/Research Disclosure InformationChulalongkorn University, Prathumwan, Thailand